Advertisement

Perioperative Pembrolizumab Plus Standard of Care for Resectable Locally Advanced HNSCC
Posted: 06/10/2025 | By: Melissa E. Fryman, MS

The addition of perioperative immune checkpoint inhibitors to standard-of-care (SOC) treatment has led to efficacy benefits across multiple tumor types. The randomized phase III KEYNOTE-689 study, presented at the 2025 AACR Annual Meeting, evaluated whether neoadjuvant and adjuvant pembrolizumab plus SOC (surgery followed by radiotherapy, with or without chemotherapy) improved event-free survival compared with SOC alone among patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Question 1 of 5

In the phase III KEYNOTE-689 study, adults with newly diagnosed resectable locally advanced HNSCC were randomized 1:1 to receive standard-of-care (SOC) treatment plus ____ cycles of neoadjuvant pembrolizumab, ____ cycles of pembrolizumab concurrent with postoperative radiotherapy, and ____ cycles of adjuvant pembrolizumab at 200 mg intravenously every 3 weeks vs SOC alone.

Choose 1

A
2 cycles; 3 cycles; 12 cycles
B
3 cycles; 2 cycles; 12 cycles
C
2 cycles; 2 cycles; 12 cycles
D
3 cycles; 3 cycles; 12 cycles

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage